Lundbeck and Otsuka Expand Alliance with Deal for Late-Stage Alzheimer’s Disease Programme

Abstract

In the largest single product licensing deal of 2013 so far, H. Lundbeck and Otsuka Pharmaceutical have partnered for the development of Lu AE58054, a selective 5HT6 receptor antagonist that has completed a Phase II trial in patients with moderate Alzheimer’s disease. Otsuka will gain co-development and co-commercialisation rights to Lu AE58054 in the US, Canada, major European countries, Nordic countries and East Asia, including Japan. The deal represents an expansion of the companies’ November 2011 alliance for the co-development and co-commercialisation of up to five CNS products.